Dualitas Therapeutics
Latest round
- Series A
Last raised
- Jul 2025
Total raised
- $65M
Investors
- 6
About Dualitas Therapeutics
Dualitas Therapeutics was founded in 2023 in San Francisco, US, specializing in innovative bispecific antibody therapies.Dualitas Therapeutics specializes in the development of innovative bispecific antibody (BsAb) therapies through its proprietary DualScreen™ Bispecific Discovery Engine. This platform operates at a combinatorial scale, allowing the identification of unique co-target combinations that harness novel cell-surface proximity mechanisms for therapeutic applications. The company’s lead programs, DTX-102 and DTX-103, focus on addressing autoimmune and allergic diseases, respectively, and have shown differentiated preclinical profiles compared to existing therapies. Dualitas serves a diverse client base within the biopharmaceutical industry, including potential partners in drug development and academic institutions focused on immunology and oncology.Dualitas Therapeutics' revenue model is anchored in strategic collaborations and partnerships with other biopharmaceutical companies and research institutions. The firm engages in B2B transactions, providing access to its DualScreen™ technology and pipeline programs, thus facilitating drug development partnerships. Revenue is generated through structured agreements, including milestone payments tied to the progression of therapeutic candidates through clinical trials and potential royalties upon successful commercialization. The company’s flagship products, including DTX-102 and DTX-103, contribute to revenue streams as they advance towards regulatory approval and market entry.In September 2025, Dualitas Therapeutics, Inc. Additionally, Dualitas plans to expand its operations into new markets, particularly in Europe and Asia, by 2025, in response to increasing demand for innovative therapeutic solutions.
Who invested in Dualitas Therapeutics
6 investors across 1 round
See all investors in Dualitas Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Jul 1, 2025
Amount
$65M
Investors
Questions about Dualitas Therapeutics
Who invested in Dualitas Therapeutics?
Dualitas Therapeutics has 6 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Dualitas Therapeutics raised?
Dualitas Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Dualitas Therapeutics last raise money?
Dualitas Therapeutics's most recent round on record is a Series A, in Jul 2025.
What does Dualitas Therapeutics do?
Dualitas Therapeutics was founded in 2023 in San Francisco, US, specializing in innovative bispecific antibody therapies.
Where is Dualitas Therapeutics headquartered?
Dualitas Therapeutics is headquartered in San Francisco, US.
Which VCs invest in companies like Dualitas Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Dualitas Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Dualitas Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.